Novel therapies for rheumatoid arthritis
- 16 October 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 15 (11) , 1427-1441
- https://doi.org/10.1517/13543784.15.11.1427
Abstract
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that causes significant morbidity and mortality. The pathogenesis outlined to date in RA consists of a cascade of pro-inflammatory cytokines and chemokines leading to the recruitment of inflammatory cells and the self perpetuation of inflammation, ultimately leading to cartilage and bone destruction. The dramatic progress in understanding the molecular immunology in RA has led to a transition from conventional treatment with aggressive immune suppression to targeted biological-based therapies that control the inflammatory pathways associated with RA. This article reviews the current biological and small-molecule therapies approved for the treatment of RA and those in development, including antibodies, tolerising agents and vaccines.Keywords
This publication has 101 references indexed in Scilit:
- Safety of extended treatment with anakinra in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006
- Lack of efficacy of a third tumour necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibodyRheumatology, 2006
- RANKL protein is expressed at the pannus–bone interface at sites of articular bone erosion in rheumatoid arthritisRheumatology, 2006
- Chemokine receptor expression in rat adjuvant‐induced arthritisArthritis & Rheumatism, 2005
- Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell ProliferationThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα TherapyThe Journal of Experimental Medicine, 2004
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Inhibition of the mitogen activated protein kinase, p38α, prevents proinflammatory cytokine induction by human adherent mononuclear leukocytes in response to lipid loadingAtherosclerosis, 2001
- Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursorsJournal of Cellular Biochemistry, 1999
- Rheumatoid ArthritisNew England Journal of Medicine, 1990